ASTEROID TRIAL ROSUVASTATIN PDF

Context: Prior intravascular ultrasound IVUS trials have demonstrated slowing or halting of atherosclerosis progression with statin therapy but have not shown convincing evidence of regression using percent atheroma volume PAV , the most rigorous IVUS measure of disease progression and regression. Objective: To assess whether very intensive statin therapy could regress coronary atherosclerosis as determined by IVUS imaging. A motorized IVUS pullback was used to assess coronary atheroma burden at baseline and after 24 months of treatment. Each pair of baseline and follow-up IVUS assessments was analyzed in a blinded fashion. Patients: Between November and October , patients had a baseline IVUS examination and received at least 1 dose of study drug. After 24 months, patients had evaluable serial IVUS examinations.

Author:Gomuro Kijind
Country:Mozambique
Language:English (Spanish)
Genre:Automotive
Published (Last):6 March 2009
Pages:52
PDF File Size:10.90 Mb
ePub File Size:17.1 Mb
ISBN:914-9-51935-167-9
Downloads:30268
Price:Free* [*Free Regsitration Required]
Uploader:Vijin



When we see less plaque after a treatment period, all the limitations aside, we believe it will be confirmed with a morbidity and mortality benefit. All patients were treated with rosuvastatin Crestor, AstraZeneca at 40 mg daily. Researchers assessed coronary atheroma burden by IVUS at 24 months. Of the patients treated with rosuvastatin, withdrew or did not have a viable IVUS reading, which left patients available for evaluation.

Nissen said the patients who withdrew were nearly identical to the ones that remained in terms of age mean age was LDL at baseline was Treatment with rosuvastatin was associated with a reduction of When researchers measured percent atheroma volume for the entire cohort, they found that For the most diseased 10 mm subsegment, regression occurred in The treatment regimen was well tolerated.

Liver enzymes were at levels similar to that seen in other statin trials and no cases of rhabdomyolysis were reported. Healio News Cardiology Imaging. Issue: April Read Next. April 01, Receive an email when new articles are posted on. Please provide your email address to receive an email when new articles are posted on.

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts. We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice slackinc. Back to Healio. Related Content.

BLACKWATER INDICTMENT PDF

ASTEROID: IVUS shows regression with rosuvastatin

Rosuvastatin therapy lowered low-density lipoprotein cholesterol to This was associated with a significant reduction in all IVUS measures of atheroma burden. These results suggest that intensive modification of lipid levels with high-dose statin therapy can promote atheroma regression. Further studies will be required to determine whether this benefit is associated with a reduction in clinical events. This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

MANUAL GENEXUS X PDF

ASTEROID trial

FREE subscriptions for doctors and students Rosuvastatin has no clinical outcome data and prescribing restrictions apply to higher doses. Therefore, it should be reserved for cautious use in difficult-to-treat cases. A statin which has been shown to reduce mortality and morbidity e.

HIDDEN CONNECTIONS FRITJOF CAPRA PDF

The ASTEROID Trial: Coronary Plaque Regression With High-Dose Statin Therapy

The top left panel illustrates the appearance of a single cross-section at baseline intravascular ultrasound examination, while the top right panel shows the same cross-section after 24 months of treatment. The bottom 2 panels illustrate the same cross-sections, but with measurements superimposed. Atheroma area was reduced from EEM indicates external elastic membrane. A motorized IVUS pullback was used to assess coronary atheroma burden at baseline and after 24 months of treatment.

FELIX GENZMER DIE EDDA PDF

When we see less plaque after a treatment period, all the limitations aside, we believe it will be confirmed with a morbidity and mortality benefit. All patients were treated with rosuvastatin Crestor, AstraZeneca at 40 mg daily. Researchers assessed coronary atheroma burden by IVUS at 24 months. Of the patients treated with rosuvastatin, withdrew or did not have a viable IVUS reading, which left patients available for evaluation. Nissen said the patients who withdrew were nearly identical to the ones that remained in terms of age mean age was LDL at baseline was

Related Articles